Charles J Sherr

USPTO Granted Patents = 12 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 106(Granted Patents)

Company Filing History:

11 out of 260

St. Jude Children's Research Hospital

patents

1 out of 190

Cold Spring Harbor Laboratory

patents

1 out of 560

Memorial Sloan Kettering Cancer Center

patents

where one patent can have more than one assignee

Years Active: 1998-2019

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10383873 - Method and kits for identifying of CDK9 inhibitors for the treatment of cancer (2019-08-20),

2. 6673902 - Cyclin D binding factor, and uses thereof (2004-01-06),

3. 6586203 - ARF-P19, a novel regulator of the mammalian cell cycle (2003-07-01),

4. 6482929 - Antibodies to ARF-p19 (2002-11-19),

5. 6407062 - ARF-P19, a novel regulator of the mammalian cell cycle (2002-06-18),

6. 6303772 - Cyclin D binding factor, and uses thereof (2001-10-16),

7. 6180763 - Cyclin D binding factor, and uses thereof (2001-01-30),

8. 6172194 - ARF-p19, a novel regulator of the mammalian cell cycle (2001-01-09),

9. 6033847 - InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and (2000-03-07),

10. 5889169 - Cell cycle regulatory protein p16 gene (1999-03-30),

11. 5876965 - Nucleic acid encoding ARF-19, a novel regulator of the mammalian cell (1999-03-02),

12. 5723313 - ARF-p19, a novel regulator of the mammalian cell cycle (1998-03-03),

Title: The Innovative Contributions of Charles J Sherr

Introduction

Charles J Sherr is a prominent inventor based in Memphis, TN, known for his significant contributions to cancer research and treatment. With a total of 12 patents to his name, Sherr has made remarkable strides in the field of molecular biology and oncology. His work focuses on understanding the mechanisms of cancer and developing targeted therapies.

Latest Patents

Among his latest patents is a method and kits for identifying CDK9 inhibitors for the treatment of cancer. This innovative method involves determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer. The presence of MYC overexpression indicates sensitivity to treatment by a CDK9 inhibitor, particularly in cancers such as carcinoma, leukemia, and lymphoma. Another notable patent is related to the Cyclin D binding factor and its uses. This invention reveals a direct interaction between D-type cyclins and a novel myb-like transcription factor, DMP1. The findings suggest that D-type cyclins regulate gene expression in an RB-independent manner, providing insights into cancer biology.

Career Highlights

Charles J Sherr has had a distinguished career, working at renowned institutions such as St. Jude Children's Research Hospital and Cold Spring Harbor Laboratory. His research has significantly advanced the understanding of cancer mechanisms and therapeutic approaches.

Collaborations

Throughout his career, Sherr has collaborated with notable colleagues, including Dawn E Quelle and Hiroshi Hirai. These collaborations have further enriched his research and contributed to the development of innovative cancer treatments.

Conclusion

Charles J Sherr's contributions to cancer research through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to impact the development of targeted therapies for cancer patients.

This text is generated by artificial intelligence and may not be accurate.